Back جيديون ريختر المحدوده ARZ قدئون ریشتر AZB Рихтер Гедеон Bulgarian Gedeon Richter Plc. Danish Gedeon Richter (Unternehmen) German Gedeon Richter Ltd. Spanish Gedeon Richter Ltd. Estonian گدئون ریشتر Persian Richter Gedeon Nyrt. French ריכטר גדעון (מפעל תרופות) HE
&sq=albert einstein&lang=en&file=File:Gedeon_Richter_Logo.svg){kind=logo} | |
&sq=albert einstein&lang=en&file=File:Richter-Gedeon-Nyrt-P5010610.jpg) | |
| Company type | Public |
|---|---|
| BPSE: RICHTER BUX Component | |
| Industry | Biotechnology Pharmaceuticals |
| Founded | 1901 |
| Founder | Gedeon Richter |
| Headquarters | |
Area served | Worldwide |
Key people | Erik Bogsch (Chairman) Gábor Orbán (CEO) |
| Products | Medicines Pharmaceuticals |
| Revenue |  US$ 2.31 billion (2022) |
| US$ 276 million (2018) | |
| US$ 121.8 million (2018) | |
| Total assets | US$ 2.7 billion (2018) |
| Total equity | US$ 2.3 billion (2018) (on 288.9 USD/HUF) |
Number of employees | 12,696 (2018) |
| Subsidiaries | Helm BioTec Medimpex Preglem |
| Website | www.gedeonrichter.com |
| Footnotes / references [1][2] | |
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.[3][4][5][6][7][8]
Gedeon Richter Plc. has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $6.6 billion as of 2018, the third largest of companies with a primary listing on the Budapest Stock Exchange. It has secondary listings on the Luxembourg Stock Exchange.[9]
Richter sells products for the central nervous system, women’s health and cardiovascular therapeutic areas among others. The company is also active in biosimilar product development.[10] The company was established in Budapest by Gedeon Richter (1872–1944), a pharmacist, in 1901.
- ^ "Annual Report 2018" (PDF). RG. Retrieved 15 Apr 2018.
- ^ "Consolidated Financial Statements 2018" (PDF). RG. Retrieved 6 May 2018.
- ^ "AbbVie, Gedeon Richter ink pact to develop & commercialize novel dopamine receptor modulators to treat neuropsychiatric diseases". Archived from the original on 2023-03-17. Retrieved 2023-03-03.
- ^ "Gedeon Richter UK Ltd". Pharmacy In Focus. Retrieved 2023-11-16.
- ^ https://www.hermes-investment.com/au/en/professional/insights/active-esg/global-emerging-markets-positive-impact-case-study-richter-gedeon-nyrt/
- ^ "AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases | AbbVie News Center".
- ^ "Gedeon Richter's first participation in the World Congress of Biological Psychiatry".
- ^ "US success offsets coronavirus impact for Gedeon Richter".
- ^ "Gedeon Richter Company Report (2018(" (PDF).
- ^ "Actavis and Gedeon Richter Plc. Announce FDA Receipt of NDA Resubmission for Cariprazine". actavis.com/. 6 Jan 2015. Archived from the original on 16 January 2015. Retrieved 13 Jan 2015.